Sera Prognostics, Inc. Appoints Ilia Ichetovkin as Vice President of Laboratory Operations
October 03, 2012 at 09:46 pm
Share
Sera Prognostics, Inc. announced the appointment of Ilia Ichetovkin, as Vice President of Laboratory Operations. Dr. Ichetovkin will lead the development and deployment of Sera's CLIA laboratory services, culminating in the commercial launch of ProNid(TM), Sera's innovative diagnostic test to predict preterm birth risk. Before joining Sera, Dr. Ichetovkin served for ten years at companies developing and providing novel diagnostic laboratory services in a number of areas of molecular oncology and maternal-fetal health.
Sera Prognostics, Inc. is a women's health diagnostic company utilizing its proprietary proteomics and bioinformatics platform, and significant data resources to enhance maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. It has built a proteomics and bioinformatics platform to characterize the biology of pregnancy and to discover and validate key protein biomarkers found in blood that are accurate predictors of dynamic changes that occur during pregnancy. Its commercial product, the PreTRM test, is a validated, commercially available blood-based biomarker test to predict the risk of a premature delivery, also known as preterm birth. The PreTRM test is a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation that provides a prediction of the expectant motherâs risk of delivering spontaneously before 37 weeksâ gestation.
SERA PROGNOSTICS, INC. 
